Skip to main content
Erschienen in: Drug Safety 7/2004

01.06.2004 | Original Research Article

Evaluation of the Extent of Under-Reporting of Serious Adverse Drug Reactions

The Case of Toxic Epidermal Necrolysis

verfasst von: Nicole Mittmann, Sandra R. Knowles, Manuel Gomez, Joel S. Fish, Robert Cartotto, Neil H. Shear

Erschienen in: Drug Safety | Ausgabe 7/2004

Einloggen, um Zugang zu erhalten

Abstract

Introduction: Toxic epidermal necrolysis (TEN) is a life-threatening adverse drug reaction (ADR) that is primarily the result of drug exposure (incidence 0.4–1.3 per million person-years). Life-threatening ADRs such as TEN should be reported to ADR monitoring programmes, which collect reports for suspected ADRs and alert the public and medical practitioners to new drug hazards. In Canada, reports are made to the Canadian Adverse Drug Reaction Monitoring Program (CADRMP).
Objective: To examine the extent of under-reporting for TEN in Canada.
Design: A retrospective case series design was used to collect all TEN cases for the period January 1995 to December 2000.
Methods: The CADRMP and 22 burn centres across Canada were contacted for all TEN patients treated during the specified time period.
Patient Groups Studied: The study population consisted of patients admitted to burn treatment sites across Canada, patient cases reported to the CADRMP and patient cases recorded by the Canadian Institute for Health Information (CIHI) hospital discharge summaries as the International Classification of Diseases Version 9 Clinical Modification (ICD-9-CM) code 695.1.
Results: Twenty-five TEN cases (six fatal) were reported to CADRMP from January 1995 to December 2000. During this period, 14 (63.6%) burn treatment sites reported admission of 250 TEN cases. Hospital discharge summaries using the ICD-9-CM code 695.1 indicated that 4349 cases were admitted to hospital during this time period and it was estimated that 15.5% (n = 674) of these cases were TEN. Using the burn facility data as the denominator, 10% (25 of 250) of TEN cases were reported to CADRMP. Using CIHI data as a denominator, only 4% (25 of 674) of TEN cases were reported to CADRMP.
Conclusions: There is serious under-reporting of TEN. Lack of reporting of life-threatening ADRs can compromise population safety. There is a need to increase awareness of ADR reporting programmes.
Literatur
1.
Zurück zum Zitat Roujeau J, Guillaume J, Fabre J, et al. Toxic epidermal necrolysis (Lyell syndrome): incidence and drug etiology in France, 1981-1985. Arch Dermatol 1990; 126: 37–42PubMedCrossRef Roujeau J, Guillaume J, Fabre J, et al. Toxic epidermal necrolysis (Lyell syndrome): incidence and drug etiology in France, 1981-1985. Arch Dermatol 1990; 126: 37–42PubMedCrossRef
2.
Zurück zum Zitat Schopf E, Stuhmer A, Rzany B, et al. Toxic epidermal necrolysis and Steven’s Johnson syndrome: an epidemiologic study from West Germany. Arch Dermatol 1991; 127: 839–42PubMedCrossRef Schopf E, Stuhmer A, Rzany B, et al. Toxic epidermal necrolysis and Steven’s Johnson syndrome: an epidemiologic study from West Germany. Arch Dermatol 1991; 127: 839–42PubMedCrossRef
3.
Zurück zum Zitat Chan H, Stern R, Arndt K, et al. The incidence of erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis: a population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol 1990; 126: 43–7PubMedCrossRef Chan H, Stern R, Arndt K, et al. The incidence of erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis: a population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol 1990; 126: 43–7PubMedCrossRef
4.
Zurück zum Zitat Palmieri T, Greenhalgh D, Saffle J, et al. A multicentre review of toxic epidermal necrolysis treated in US burn centres at the end of the twentieth century. J Burn Care Rehabil 2002; 23: 87–96PubMedCrossRef Palmieri T, Greenhalgh D, Saffle J, et al. A multicentre review of toxic epidermal necrolysis treated in US burn centres at the end of the twentieth century. J Burn Care Rehabil 2002; 23: 87–96PubMedCrossRef
5.
Zurück zum Zitat Revuz J, Penso D, Roujeau J, et al. Toxic epidermal necrolysis: clinical findings and prognosis factors in 87 patients. Arch Dermatol 1987; 123: 1160–5PubMedCrossRef Revuz J, Penso D, Roujeau J, et al. Toxic epidermal necrolysis: clinical findings and prognosis factors in 87 patients. Arch Dermatol 1987; 123: 1160–5PubMedCrossRef
6.
Zurück zum Zitat Heimach D, Engrav L, Marvin J, et al. Toxic epidermal necrolysis: a step forward in treatment. JAMA 1987; 257: 2171–5CrossRef Heimach D, Engrav L, Marvin J, et al. Toxic epidermal necrolysis: a step forward in treatment. JAMA 1987; 257: 2171–5CrossRef
7.
8.
Zurück zum Zitat Eisen E, Fish J, Shear N. Management of drug-induced toxic epidermal necrolysis. J Cutan Med Surg 2000; 4(2): 96–102PubMed Eisen E, Fish J, Shear N. Management of drug-induced toxic epidermal necrolysis. J Cutan Med Surg 2000; 4(2): 96–102PubMed
10.
Zurück zum Zitat Schwartz R. Toxic epidermal necrolysis. Cutis 1997; 59: 123–7PubMed Schwartz R. Toxic epidermal necrolysis. Cutis 1997; 59: 123–7PubMed
11.
12.
Zurück zum Zitat Halebian P, Madden M, Finkelstein J, et al. Improved burn centre survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann Surg 1986; 204: 503–12PubMedCrossRef Halebian P, Madden M, Finkelstein J, et al. Improved burn centre survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann Surg 1986; 204: 503–12PubMedCrossRef
13.
Zurück zum Zitat Avakian R, Flowers F, Araujo O, et al. Toxic epidermal necrolysis: a review. J Am Acad Dermatol 1991; 25: 69–79PubMedCrossRef Avakian R, Flowers F, Araujo O, et al. Toxic epidermal necrolysis: a review. J Am Acad Dermatol 1991; 25: 69–79PubMedCrossRef
14.
Zurück zum Zitat Stern R, Chan H. Usefulness of case report literature in determining drugs responsible for toxic epidermal necrolysis. J Am Acad Dermatol 1989; 21: 317–22PubMedCrossRef Stern R, Chan H. Usefulness of case report literature in determining drugs responsible for toxic epidermal necrolysis. J Am Acad Dermatol 1989; 21: 317–22PubMedCrossRef
15.
Zurück zum Zitat Roujeau J, Kelly J, Naldi L, et al. Medication use and risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995; 333: 1600–7PubMedCrossRef Roujeau J, Kelly J, Naldi L, et al. Medication use and risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995; 333: 1600–7PubMedCrossRef
16.
Zurück zum Zitat MEDWATCH. The clinical impact of adverse event reporting. Washington, DC: Department of Health and Human Services, 1996 MEDWATCH. The clinical impact of adverse event reporting. Washington, DC: Department of Health and Human Services, 1996
17.
Zurück zum Zitat Naranjo C, Busto U. Adverse drug reactions. In: Kalant H, Roschlau W, editors. Principles in medical pharmacology. 5th ed. Toronto: BC Decker, 1989: 658–65 Naranjo C, Busto U. Adverse drug reactions. In: Kalant H, Roschlau W, editors. Principles in medical pharmacology. 5th ed. Toronto: BC Decker, 1989: 658–65
18.
Zurück zum Zitat Canadian Institute for Health Information (CIHI) [online]. Available from URL: http://www.cihi.ca [Accessed 2004 Apr] Canadian Institute for Health Information (CIHI) [online]. Available from URL: http://​www.​cihi.​ca [Accessed 2004 Apr]
19.
Zurück zum Zitat Statistics Canada, Population Estimates [online]. Available from URL: http://www.statcan [Accessed 2004 Apr 21]. ca/Daily/English/00 0926, 2000 Statistics Canada, Population Estimates [online]. Available from URL: http://​www.​statcan [Accessed 2004 Apr 21]. ca/Daily/English/00 0926, 2000
20.
Zurück zum Zitat Health Canada. Canadian adverse drug reaction newsletter. Ottawa (ON): Therapeutic Products Programme, 2003 Health Canada. Canadian adverse drug reaction newsletter. Ottawa (ON): Therapeutic Products Programme, 2003
21.
Zurück zum Zitat US FDA Annual Adverse Drug Experiences Report 1996 [online]. Available from URL: http://www.fda.gov/medwatch/articles.htm [Accessed 2004 Apr] US FDA Annual Adverse Drug Experiences Report 1996 [online]. Available from URL: http://​www.​fda.​gov/​medwatch/​articles.​htm [Accessed 2004 Apr]
22.
Zurück zum Zitat Venning G. Identification of adverse reactions to new drugs III: altering process and early warning. BMJ 1983; 286: 458–60PubMedCrossRef Venning G. Identification of adverse reactions to new drugs III: altering process and early warning. BMJ 1983; 286: 458–60PubMedCrossRef
23.
Zurück zum Zitat Capella D, Laporte J, Vidal X, et al. European network for the case-population surveillance of rare disease (Euronet): a prospective feasibility study. Eur J Clin Pharmacol 1998; 53: 299–302PubMedCrossRef Capella D, Laporte J, Vidal X, et al. European network for the case-population surveillance of rare disease (Euronet): a prospective feasibility study. Eur J Clin Pharmacol 1998; 53: 299–302PubMedCrossRef
24.
Zurück zum Zitat Mockenhaupt M, Schopf E. Epidemiology of drug-induced severe skin reactions. Semin Cutan Med Surg 1996; 15(4): 236–43PubMedCrossRef Mockenhaupt M, Schopf E. Epidemiology of drug-induced severe skin reactions. Semin Cutan Med Surg 1996; 15(4): 236–43PubMedCrossRef
25.
Zurück zum Zitat Meyboom R, Egberts A, Edwards I, et al. Principles of signal detection on Pharmacovigilance. Drug Saf 1997; 16(6): 355–65PubMedCrossRef Meyboom R, Egberts A, Edwards I, et al. Principles of signal detection on Pharmacovigilance. Drug Saf 1997; 16(6): 355–65PubMedCrossRef
26.
Zurück zum Zitat Olsson S. The role of the WHO programme on international drug monitoring in coordinating world-wide drug safety efforts. Drug Saf 1998; 19(1): 1–10PubMedCrossRef Olsson S. The role of the WHO programme on international drug monitoring in coordinating world-wide drug safety efforts. Drug Saf 1998; 19(1): 1–10PubMedCrossRef
27.
Zurück zum Zitat Ionnidis J, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA 2001; 285: 437–43CrossRef Ionnidis J, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA 2001; 285: 437–43CrossRef
28.
Zurück zum Zitat Inman W. Study of fatal bone marrow depression with special reference to phenylbutazone and oxybutazone. BMJ 1977; 1: 1500–5PubMedCrossRef Inman W. Study of fatal bone marrow depression with special reference to phenylbutazone and oxybutazone. BMJ 1977; 1: 1500–5PubMedCrossRef
29.
Zurück zum Zitat Scott H, Rosenbaum S, Waters W, et al. Rhode Island physician’s recognition and reporting of adverse drug reactions. R I Med J 1987; 70: 311–6PubMed Scott H, Rosenbaum S, Waters W, et al. Rhode Island physician’s recognition and reporting of adverse drug reactions. R I Med J 1987; 70: 311–6PubMed
30.
Zurück zum Zitat Alvarez-Requejo A, Carvajal A, Begaud B, et al. Under-reporting of adverse drug reactions: estimate based on a spontaneous reporting scheme and a sentinel system. Eur J Clin Pharm 1998; 54: 483–8CrossRef Alvarez-Requejo A, Carvajal A, Begaud B, et al. Under-reporting of adverse drug reactions: estimate based on a spontaneous reporting scheme and a sentinel system. Eur J Clin Pharm 1998; 54: 483–8CrossRef
31.
Zurück zum Zitat Moride Y, Haramburu F, Requejo A, et al. Under-reporting of adverse drug reactions in general practice. Br J Clin Pharmacol 1997; 43: 177–81PubMedCrossRef Moride Y, Haramburu F, Requejo A, et al. Under-reporting of adverse drug reactions in general practice. Br J Clin Pharmacol 1997; 43: 177–81PubMedCrossRef
32.
Zurück zum Zitat Belton K. Attitude survey of adverse drug-reaction reporting by healthcare professionals across the European Union. Eur J Clin Pharm 1997; 52(6): 423–7CrossRef Belton K. Attitude survey of adverse drug-reaction reporting by healthcare professionals across the European Union. Eur J Clin Pharm 1997; 52(6): 423–7CrossRef
33.
Zurück zum Zitat LaCalamita S. Top 10 reasons for not reporting adverse drug reactions. Hosp Pharm 1995; 30(3): 245–6PubMed LaCalamita S. Top 10 reasons for not reporting adverse drug reactions. Hosp Pharm 1995; 30(3): 245–6PubMed
34.
Zurück zum Zitat Colodny L, Spillane J. Toward increased reporting of adverse drug reactions. Hosp Pharm 1999; 34(10): 1179–85 Colodny L, Spillane J. Toward increased reporting of adverse drug reactions. Hosp Pharm 1999; 34(10): 1179–85
35.
Zurück zum Zitat Mittmann N, Liu BA, Iskedjian M, et al. Drug-related deaths in Canada (1984-1994). Pharmacoepidemiol Drug Saf 1997; 6: 157–68PubMedCrossRef Mittmann N, Liu BA, Iskedjian M, et al. Drug-related deaths in Canada (1984-1994). Pharmacoepidemiol Drug Saf 1997; 6: 157–68PubMedCrossRef
36.
Zurück zum Zitat Statistics Canada Population, 2000 [online]. Available from URL: http://www.statcan [Accessed 2004 Apr 21] Statistics Canada Population, 2000 [online]. Available from URL: http://​www.​statcan [Accessed 2004 Apr 21]
Metadaten
Titel
Evaluation of the Extent of Under-Reporting of Serious Adverse Drug Reactions
The Case of Toxic Epidermal Necrolysis
verfasst von
Nicole Mittmann
Sandra R. Knowles
Manuel Gomez
Joel S. Fish
Robert Cartotto
Neil H. Shear
Publikationsdatum
01.06.2004
Verlag
Springer International Publishing
Erschienen in
Drug Safety / Ausgabe 7/2004
Print ISSN: 0114-5916
Elektronische ISSN: 1179-1942
DOI
https://doi.org/10.2165/00002018-200427070-00004